Human Healthcare Revenue (Q4)
₹1,281M
+24% YoY
Largest segment contributed 63% of total revenue, driven by pharma API and biocatalysis.
ADVANCEDENZYMETECHNOLOGI
Information Technology
2026-04-??
Advanced Enzyme Technologies Ltd — Q4 FY26
Advanced Enzyme delivered a record quarter with revenue of ₹203.4 crore (+22% YoY) and EBITDA of ₹63.2 crore (+39% YoY), driven by strong volume growth in human healthcare (up 24% YoY) and biocatalysis.
✓ Verified against BSE filing
2-Min Summary
Advanced Enzyme delivered a record quarter with revenue of ₹203.4 crore (+22% YoY) and EBITDA of ₹63.2 crore (+39% YoY), driven by strong volume growth in human healthcare (up 24% YoY) and biocatalysis. PAT surged 69% YoY to ₹45.3 crore, with margins steady at 31%. The India business grew ~50% YoY, while US remained soft due to tariff uncertainty and inflation. Management expects double-digit growth in FY27, supported by new R&D facility operational in H2, EU approval for an anti-inflammatory product, and capacity expansion plans. Key risk: US tariff and inflation headwinds could pressure margins and delay recovery.
Key Numbers
Serratiopeptidase Growth (FY26)
45%
+45% YoY
Key product saw 45% annual growth; Q4 growth was 54% YoY.
Biocatalysis Revenue (FY26)
₹247M
+42% YoY
Biocatalysis revenue grew from ₹174M to ₹247M, reflecting strong demand.
India Business Share (Human Nutrition)
32%
+?pp YoY
Domestic human nutrition contributed 32% of total revenue, indicating balanced geographic mix.
Management Guidance
Double-digit revenue growth in FY27
Management expects double-digit growth for FY27, driven by all segments including human, animal, and food.
revenueEBITDA margin to remain around 31%
Margins expected to be steady with possible 1-2% variability due to cost pressures.
marginsNew R&D center operational in H2 FY27
The new R&D center in Nashik will be fully operational in the second half of FY27, boosting product development capacity threefold.
capexEU approval for anti-inflammatory product expected in FY27
The product filed two years ago is anticipated to receive EU approval this year, providing exclusivity for 5-10 years.
growthKey Risks
US tariff and inflation impact
US business faces 18% tariff and rising inflation, pressuring margins and demand. Management is absorbing ~10% cost increase.
high · management_commentaryGross margin pressure from product mix
Analyst noted sequential gross margin decline; management attributed to product mix and higher domestic sales, which carry lower margins.
medium · analyst_questionKey management departure
Mr. Deepak Lala, a long-time executive, has left. Management stated roles are split between two heads, but transition risk remains.
medium · analyst_questionGeopolitical supply chain disruptions
Conflicts and trade restrictions could escalate input costs (fuel, solvents, packaging) and logistics, impacting margins.
medium · management_commentaryNotable Quotes
We have reported our highest ever quarterly and annual revenue for the fiscal year ended March 2026.
If it gets approved then we will be the only person who can supply that product for next five years or 10 years.
This is going to be a very challenging year no matter what.